Spero Therapeutics, Inc. (SPRO): Operating Cash Flow
-$12.62M
Year ended 2025-12-31
$19.58M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$12.62M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$23.44M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$32.99M | n/m | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | -$7.73M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$64.35M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$85.87M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$50.02M | n/m | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | -$39.62M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$39.11M | n/m | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | -$28.96M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$9.61M | n/a | 2018-04-02, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | -$64.06M | n/m |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$19.27M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$659.0K | n/m |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | -$65.78M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$276.39M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$173.43M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$138.89M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$41.09M | n/m |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗